蘇大維格(300331.SZ):擬向控股子公司提供合計不超1.6億元財務資助
格隆匯3月11日丨蘇大維格(300331.SZ)公佈,為支持公司控股子公司維業達及邁塔光電業務發展,滿足其資金週轉及日常經營需要,降低公司財務成本、提高資金使用效率,在不影響公司正常經營的前提下,公司擬以自有資金向控股子公司維業達提供不超過1億元人民幣的財務資助額度、向邁塔光電提供不超過6000萬元人民幣的財務資助額度,期限為自公司股東大會審議通過之日起一年內簽訂財務資助合同有效,借款利率不低於中國人民銀行公佈的同期貸款基準利率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.